Our Mission
To increase the number of quality years lived by those with under-served health conditions, transforming the standard of care for chronic, underserved health conditions
Our Story
Neuraura Biotech Inc., was founded to improve the lives of millions of people suffering from neurological, psychiatric and sensory conditions by leveraging our novel electrode technology to enhance diagnostic and therapeutic solutions across treatment modalities.
​
Neuraura was incorporated in December 2017 to commercialize the technology and the company negotiated a landmark technology transfer deal with the University of Calgary. Neuraura secured its initial pre-seed funding in October 2018 through the Creative Destruction Lab (CDL) network and formally established its core team shortly thereafter.
​
Neuraura’s unfair advantage stems from its unique, proprietary micro-electrodes. For recording they offer extremely high-fidelity data (low noise, high granularity) which enables visibility of signals which are otherwise impossible to make out amongst the noise. For percutaneous stimulation, they slightly penetrate the dermis overcoming the natural barrier the skin provides; their rigidity also can be adapted so, for example, they do not cause damage to the skin as repeated use of stainless steel micro-electrodes can do.
​
Neuraura’s microsensors represent the culmination of decades of fundamental research in neuroscience at the Hotchkiss Brain Institute at the University of Calgary, combined with leading manufacturing practices from the silicon chip industry. The novel 3D microsensors were designed based on world-leading expertise in neuro-engineering and microfabrication as part of Dr. Pierre Wijdenes’ PhD studies.
Our Team
Neuraura is led by Claire Dixon and Pierre Wijdenes, co-founders with a shared vision to transform the standard of care for chronic, underserved conditions. Claire and Pierre have been working together since 2017 when Neuraura was formed as part of the inaugural cohort of the Creative Destruction Lab Rockies. They are supported by an outstanding team of scientific, clinical and commercial advisors.
Claire Dixon, MBA MEng MA (Cantab.)
CEO and Co-Founder
Claire has 25+ years’ international leadership, strategy and operational experience, including 15 years as a strategic consultant to capital and technology-intensive businesses, 5 years in senior operational roles and 7 years as a deeptech founder. She holds an MBA from Harvard Business School and a MEng/MA (Cantab.) in Mechanical Engineering from Cambridge University. Claire was recently named one of the Top 200 Trailblazing Leaders in FemTech and Women’s Health by Women of Wearables
Pierre Wijdenes, PhD
CPO and Co-Founder
Pierre completed his Doctorate in Biomedical Engineering at the University of Calgary in 2017 and also spent time with the National Research Council of Canada. As part of his studies, Pierre took advantage of Introduction to Entrepreneurship and Innovation and New Venture Development courses to develop his business acumen. Pierre also holds a MEng/MSc in Human Factors, Cognitive Engineering and User Interaction from the École Nationale Supérieure de Cognitique (“ENSC”) in Bordeaux - France.